Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. Quaker BioVentures invests in companies at all stages of development, from early stage start-ups to public companies. Founded in 2003, the firm is currently investing Quaker BioVentures II, a $420 million fund formed in 2007. Quaker BioVentures manages over $700 million in committed capital.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2007 | Optherion | Series A | 37M |
11/2007 | Tranzyme | Venture Round | 20M |
1/2011 | RainDance Technologies | Series D | 37.5M |
10/2009 | Sleep Solutions | Series F | 20M |
8/2010 | Achillion Pharmaceuticals | Post-IPO Equity | 50.1M |
10/2008 | Biolex Therapeutics | Series D | 0 |
10/2009 | Neuronetics | Series D | 0 |
5/2005 | Celator Pharmaceuticals | Series B | 20M |
9/2012 | Intact Vascular | Series A | 15.5M |
10/2008 | Corridor Pharmaceuticals | Seed Round | 0 |
8/2003 | Biolex Therapeutics | Venture Round | 0 |
12/2009 | Regado Biosciences | Series D | 0 |
6/2007 | Argolyn Bioscience | Series A | 15.8M |
1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
11/2008 | Tengion | Series C | 0 |
3/2006 | Nitric Bio | Series A | 14M |
3/2007 | Regado Biosciences | Series C | 23M |
3/2006 | Helomics | Venture Round | 20M |
4/2013 | RainDance Technologies | Series E | 0 |
12/2002 | BioRexis | Series A | 8M |
4/2004 | MedMark Treatment Centers | Venture Round | 28M |
6/2010 | Helomics | Series D | 33M |
8/2009 | Rapid Micro Biosystems | Series A | 18.6M |
6/2009 | Cempra | Series C | 46M |
1/2010 | Tarsa Therapeutics | Series A | 24M |
9/2013 | PreCision Dermatology | Debt Financing | 67M |
1/2010 | BioLeap | Series A | 5M |
4/2005 | TargetRx | Series D | 0 |
6/2004 | Nucleonics | Series B | 49.2M |
9/2005 | Amicus Therapeutics | Series C | 55M |
6/2006 | TetraLogic Pharmaceuticals | Series B | 36M |
6/2011 | NovaSom | Series D | 35M |
3/2004 | BioRexis | Series B | 30M |
2/2005 | Neotropix | Series A | 10M |
3/2008 | EKR Therapeutics | Series D | 50M |
7/2008 | Celator Pharmaceuticals | Series C | 22.5M |
8/2007 | Celator Pharmaceuticals | Series C | 10M |
9/2010 | Celator Pharmaceuticals | Series D | 0 |
10/2007 | Tengion | Series C | 33M |
6/2006 | Tengion | Series B | 50M |
5/2010 | TearScience | Series C | 44.5M |
8/2010 | TetraLogic Pharmaceuticals | Series C | 0 |
9/2006 | Amicus Therapeutics | Series D | 60M |
5/2011 | Neuronetics | Series E | 30M |
4/2015 | Neuronetics | Series F | 0 |
9/2005 | Biolex Therapeutics | Series B | 36M |
5/2007 | Biolex Therapeutics | Series C | 30M |
6/2010 | Corridor Pharmaceuticals | Series A | 0 |
4/2008 | Transave | Series D | 35M |
3/2012 | Tarsa Therapeutics | Series B | 28M |
3/2019 | Kaarta | Series A | 0 |
11/2008 | Helomics | Venture Round | 43M |
7/2008 | NuPathe | Series B | 30M |
4/2008 | Diasome Pharmaceuticals | Series B | 8.4M |
8/2007 | EKR Therapeutics | Series C | 13M |
4/2007 | StageMark | Series B | 1.6M |
10/2009 | Asensus Surgical | Post-IPO Equity | 0 |
5/2005 | Tranzyme | Series A | - |
3/2019 | Kaarta | Series A | 0 |
4/2015 | Neuronetics | Series F | 0 |
9/2013 | PreCision Dermatology | Debt Financing | 0 |
4/2013 | RainDance Technologies | Series E | 0 |
9/2012 | Intact Vascular | Series A | 0 |
3/2012 | Tarsa Therapeutics | Series B | 0 |
6/2011 | NovaSom | Series D | 0 |
5/2011 | Neuronetics | Series E | 0 |
1/2011 | RainDance Technologies | Series D | 0 |
1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|